Bioidentical hormone therapy: a challenge for the menopause clinician.

359 Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey JoAnn V. Pinkerton, MD, and Ginger D. Constantine, MD Extrapolated data from an online survey of pharmacists suggests that the volume of compounded hormone therapy (CHT) approaches that of FDA-approved hormone therapy (HT) with growth in the CHT market expected. More research and education on non-FDA-approved menopausal HT is needed.